I'm LongbridgeAI, I can summarize articles.NKGen Biotech amended its $5 million loan agreement with BDW Investments, replacing the all-assets security pledge with a first-priority lien on specific real estate. The amendment clarifies collateral priorities, bars other senior liens, and aligns the Senior Loan definition with a separate convertible facility. This change aims to better structure the company's capital stack while releasing certain claims in favor of the lender.
NKGen Biotech entered into a First Amendment to its Equity and Business Loan Agreement with BDW Investments, updating the $5 million multi-draw term loan. The amendment replaces the prior all-assets security approach with a first-priority perfected lien on specified real estate and bars other senior liens on that collateral, except customary ones. It also updates the definition of the company’s Senior Loan to reference the April 15, 2026 senior convertible facility with AlpineBrook and includes a release of claims in favor of the lender. The changes clarify collateral priorities and align the loan with NKGen’s capital structure.
Agreement details:
- Agreement type: First Amendment to Equity and Business Loan Agreement for $5 million multi-draw term loan
- Counterparty: BDW Investments
- Signed / Effective: Jul 13 2026 / Jul 13 2026
- Reason: Update collateral and align with senior convertible financing
Original SEC Filing: NKGen Biotech, Inc. [ NKGN ] - 8-K - Jul. 17, 2026